Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pharmacokinetic study of levetiracetam in children.

Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, Shields WD.

Epilepsia. 2001 Dec;42(12):1574-9.

2.

Pharmacokinetics of levetiracetam in infants and young children with epilepsy.

Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, Stockis A, Lu ZS.

Epilepsia. 2007 Jun;48(6):1117-22. Epub 2007 Apr 18.

3.

Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.

Fountain NB, Conry JA, Rodríguez-Leyva I, Gutierrez-Moctezuma J, Salas E, Coupez R, Stockis A, Lu ZS.

Epilepsy Res. 2007 Apr;74(1):60-9. Epub 2007 Jan 31.

PMID:
17270398
4.

Age and comedications influence levetiracetam pharmacokinetics in children.

Dahlin MG, Wide K, Ohman I.

Pediatr Neurol. 2010 Oct;43(4):231-5. doi: 10.1016/j.pediatrneurol.2010.05.008.

PMID:
20837299
5.
6.

Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.

Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A.

Clin Pharmacokinet. 2008;47(5):333-41.

PMID:
18399714
7.

Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.

Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G.

Epilepsia. 2009 May;50(5):1150-7. doi: 10.1111/j.1528-1167.2008.01974.x. Epub 2009 Jan 19.

8.

Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.

Johannessen Landmark C, Baftiu A, Tysse I, Valsø B, Larsson PG, Rytter E, Johannessen SI.

Ther Drug Monit. 2012 Aug;34(4):440-5. doi: 10.1097/FTD.0b013e31825ee389.

PMID:
22777154
9.

Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.

Brockmöller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I.

Clin Pharmacol Ther. 2005 Jun;77(6):529-41.

PMID:
15961984
10.
11.

Population pharmacokinetics of levetiracetam in Japanese and Western adults.

Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A.

Clin Pharmacokinet. 2007;46(6):503-12.

PMID:
17518509
12.

Preliminary efficacy of levetiracetam in children.

Glauser TA, Dulac O.

Epileptic Disord. 2003 May;5 Suppl 1:S45-50. Review.

PMID:
12915341
13.

Use of levetiracetam in special populations.

French J.

Epilepsia. 2001;42 Suppl 4:40-3. Review.

14.

Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.

Contin M, Albani F, Riva R, Baruzzi A.

Ther Drug Monit. 2004 Aug;26(4):375-9.

PMID:
15257066
15.

Pharmacokinetics of levetiracetam.

Radtke RA.

Epilepsia. 2001;42 Suppl 4:24-7. Review.

16.

Levetiracetam in refractory pediatric epilepsy.

Wheless JW, Ng YT.

J Child Neurol. 2002 Jun;17(6):413-5.

PMID:
12174960
17.

The pharmacokinetic characteristics of levetiracetam.

Patsalos PN.

Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):123-9. Review.

PMID:
12731458
18.

Pharmacokinetic profile of levetiracetam: toward ideal characteristics.

Patsalos PN.

Pharmacol Ther. 2000 Feb;85(2):77-85. Review.

PMID:
10722121
19.

[Characteristics and indications of levetiracetam].

Herranz JL, Argumosa A.

Rev Neurol. 2002 Sep;35 Suppl 1:S110-6. Review. Spanish.

20.

Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy.

Freitas-Lima P, Alexandre V Jr, Pereira LR, Feletti F, Perucca E, Sakamoto AC.

Epilepsy Res. 2011 Mar;94(1-2):117-20. doi: 10.1016/j.eplepsyres.2011.01.007. Epub 2011 Feb 1.

PMID:
21282041
Items per page

Supplemental Content

Write to the Help Desk